๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders

โœ Scribed by C.-H. Lieu; H.-S. Wu; Y.-C. Hon; W.-H. Tsai; C.-F. Yang; C.-C. Wang; Y.-C. Lin; C.-H. Shih; H.-C. Hsu

Book ID
109003238
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
103 KB
Volume
38
Category
Article
ISSN
1444-0903

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The V617F JAK2 mutation and the myelopro
The V617F JAK2 mutation and the myeloproliferative disorders
โœ Melanie J Percy; Mary Frances McMullin ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB

## Abstract The discovery this year of a single mutation in the Janus Kinase (__JAK__)โ€2 gene in a high percentage of cases of polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis suggests that it maybe the underlying molecular mechanism for these disorders. Different approach

Correlations of JAK2โ€“V617F mutation with
Correlations of JAK2โ€“V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders
โœ Matthaios Speletas; Eirini Katodritou; Chrisoula Daiou; Eudokia Mandala; Emmanou ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 212 KB

Recently, the acquired mutation JAK2-V617F has been described in the majority of patients with myeloproliferative disorders (MPDs). In this study we evaluated its clinical and laboratory correlates in 166 patients with MPDs. The mutation was detected by allele-specific PCR in 119 patients: 81.4% (35